Peer-reviewed veterinary case report
Dogs with high-grade mediastinal lymphoma signs and survival
By Moore, E L et al.·Published in Veterinary and comparative oncology·2018·William R. Pritchard Veterinary Medical Teaching Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with high-grade primary mediastinal lymphoma showed symptoms like tiredness, loss of appetite, and increased thirst and urination. Most of these dogs were treated with a chemotherapy protocol called CHOP (which includes cyclophosphamide, doxorubicin, vincristine, and prednisone), leading to better survival times compared to other treatments. On average, dogs treated with CHOP lived about 194 days after diagnosis, while those receiving different therapies had shorter survival times. Although the overall outlook for this condition is challenging, using the CHOP protocol can help improve the length of life for affected dogs.
People also search for: dog lymphoma treatment · high-grade lymphoma symptoms in dogs · CHOP protocol for dogs
Abstract
The goals of this retrospective study were to determine the patient characteristics of dogs with high-grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow-up information available. The most common clinical signs included lethargy, anorexia and polyuria/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T-cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (WHO) lymphoma classification scheme. The overall progression-free survival (PFS) and overall survival (OS) were 133 and 183 days, respectively. Treatment with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) protocol was associated with an improved PFS (144 days) and OS (194 days) when compared with dogs that received other medical therapies (P = .005 and P = .002, respectively); the absence of pleural effusion at diagnosis was associated with an increased OS but not PFS. These results suggest that while the prognosis for dogs with mediastinal lymphoma is poor, survival may be improved with treatment using a CHOP-based protocol.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28660709/